(Q38195260)

30 August 2017

1 reference

title

Epigenetics and oncology (English)

1 reference

30 August 2017

1 reference

Padmaja Mummaneni

1

1 reference

30 August 2017

Stacy S Shord

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

11 March 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

34

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

495-505

1 reference

Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology

30 August 2017

cites work

1 reference

Epigenetics: a landscape takes shape

21 January 2018

1 reference

The epigenomics of cancer

21 January 2018

1 reference

Epigenetic modifications and human disease

21 January 2018

1 reference

Epigenetic modifications as therapeutic targets

21 January 2018

1 reference

Epigenetics and colorectal cancer

21 January 2018

1 reference

Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation

21 January 2018

1 reference

Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors.

21 January 2018

1 reference

Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma

21 January 2018

1 reference

Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation

21 January 2018

1 reference

5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations

21 January 2018

1 reference

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

21 January 2018

1 reference

5-hydroxymethylcytosine and its potential roles in development and cancer.

21 January 2018

1 reference

A landscape of driver mutations in melanoma

21 January 2018

1 reference

Oncogenic driver mutations in lung cancer.

21 January 2018

1 reference

21 January 2018

1 reference

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

21 January 2018

1 reference

The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores

21 January 2018

1 reference

Cancer epigenetics: modifications, screening, and therapy

21 January 2018

1 reference

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

21 January 2018

1 reference

Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73

21 January 2018

1 reference

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

Epigenetics as a mechanism driving polygenic clinical drug resistance

21 January 2018

1 reference

DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies

21 January 2018

1 reference

Identification of driver and passenger DNA methylation in cancer by epigenomic analysis

21 January 2018

1 reference

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells

21 January 2018

1 reference

Decitabine: a historical review of the development of an epigenetic drug

21 January 2018

1 reference

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

21 January 2018

1 reference

Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.

21 January 2018

1 reference

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura

21 January 2018

1 reference

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.

21 January 2018

1 reference

Epigenetics: The Role of Methylation in the Mechanism of Action of Tumor Suppressor Genes

21 January 2018

1 reference

Multiple roles of class I HDACs in proliferation, differentiation, and development

21 January 2018

1 reference

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

Romidepsin: a novel histone deacetylase inhibitor for cancer

21 January 2018

1 reference

Histone deacetylase inhibitors: discovery and development as anticancer agents

21 January 2018

1 reference

Targeting histone deacetylases: development of vorinostat for the treatment of cancer

21 January 2018

1 reference

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

21 January 2018

1 reference

Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide

21 January 2018

1 reference

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

21 January 2018

1 reference

New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome

21 January 2018

1 reference

DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes

21 January 2018

1 reference

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

21 January 2018

1 reference

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer

21 January 2018

1 reference

Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance

21 January 2018

1 reference

The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients

21 January 2018

1 reference

A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer

21 January 2018

1 reference

Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling

21 January 2018

1 reference

The epigenetics of ovarian cancer drug resistance and resensitization

21 January 2018

1 reference

A decade of exploring the cancer epigenome - biological and translational implications

21 January 2018

1 reference

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

21 January 2018

1 reference

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines

21 January 2018

1 reference

Histone deacetylase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

21 January 2018

1 reference

The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells

21 January 2018

1 reference

Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML.

21 January 2018

1 reference

Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines

21 January 2018

1 reference

Advancing breast cancer therapy by translational research: highlights of the Improving Care and Knowledge through Translational Research (IMPAKT) breast cancer conference

21 January 2018

1 reference

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers

21 January 2018

1 reference

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

Decitabine in chronic leukemias

21 January 2018

1 reference

Outcome in adult low-grade glioma: the impact of prognostic factors and treatment

21 January 2018

1 reference

MGMT methylation: a marker of response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.

21 January 2018

1 reference

Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening

21 January 2018

1 reference

Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk.

21 January 2018

1 reference

Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population.

21 January 2018

1 reference

A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection

21 January 2018

1 reference

Genetic and epigenetic marker-based DNA test of stool is a promising approach for colorectal cancer screening.

21 January 2018

1 reference

Circulating methylated septin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1408

1 reference

30 August 2017

1 reference